• Organizations: Bausch + Lomb
B+L Consumer Summit highlights OTC integration as key to managing ocular surface health
Events

B+L Consumer Summit highlights OTC integration as key to managing ocular surface health

Clinicians emphasize over-the-counter options as a first-line treatment for ocular surface disease during Bausch + Lomb’s one-day consumer summit.
FDA clears Bausch + Lomb's Bi-Blade+ vitrectomy cutter and fluidics technology
Products

FDA clears Bausch + Lomb's Bi-Blade+ vitrectomy cutter and fluidics technology

Dual-port vitrectomy cutter increases cutting speed from 15K to 25K per minute, while Adaptive Fluidics update expands capabilities of the Stellaris Elite system
Positive 24-month data supports the Elios System for glaucoma treatment
Pipeline

Positive 24-month data supports the Elios System for glaucoma treatment

Microinvasive, implant-free procedure used excimer laser technology to lower IOP by 20% or greater among 76% of glaucoma and cataract patients
Study: enVista Aspire IOL delivers expanded intermediate vision without sacrificing distance
Research

Study: enVista Aspire IOL delivers expanded intermediate vision without sacrificing distance

Prospective study evaluates the enhanced monofocal IOL among patients undergoing standard phaco.
Bausch + Lomb and Ripple Therapeutics partner to develop sustained-release implants
Business

Bausch + Lomb and Ripple Therapeutics partner to develop sustained-release implants

Collaboration involves the Epidel prodrug platform, which engineers polymer-free drugs with customized, repeat doses and durations for ophthalmic diseases.
Pivotal study showcases enVista Envy IOL's full range of vision
Research

Pivotal study showcases enVista Envy IOL's full range of vision

Data includes meeting all efficacy and safety outcomes, with the lens demonstrating statistical superiority in visual outcomes and a favorable dysphotopsia profile.
New data reinforces XIIDRA's eye dryness relief among CL wearers
Research

New data reinforces XIIDRA's eye dryness relief among CL wearers

Open-label study evaluated effectiveness of lifitegrast 5%, noting significant improvements in end-of-day dryness and discomfort in just 2 weeks.
Bausch + Lomb launches ASANA gas permeable lenses
Products

Bausch + Lomb launches ASANA gas permeable lenses

Latest addition to the company’s GP lens portfolio is a versatile lens custom designed to provide advanced visual acuity and all-day shape maintenance.
New phase 3 data compares efficacy of Lumify PF to Lumify drops for ocular redness reduction
Research

New phase 3 data compares efficacy of Lumify PF to Lumify drops for ocular redness reduction

Randomized trial reports favorable outcomes in evaluating the safety and efficacy of the preservative-free brimonidine tartrate (0.025%) formulation.
Leadership watch: PolyActiva, B+L, and Wills Eye make strategic changes
Business

Leadership watch: PolyActiva, B+L, and Wills Eye make strategic changes

Check out the latest leadership news from the eyecare space, including two new execs at PolyActiva and a retinal disorder treatment specialist taking the helm at Wills Eye.
Bausch + Lomb unveils 2025 state of dry eye survey results
Research

Bausch + Lomb unveils 2025 state of dry eye survey results

Building on 2024 findings, latest results indicate a need for more patient education to dispel ongoing misconceptions surrounding dry eye.
Bausch + Lomb launches two new eye drops to Blink portfolio
Products

Bausch + Lomb launches two new eye drops to Blink portfolio

Now available at most U.S. retailers, the latest additions to this specialty product line includes Blink Nourish Lubricating and Blink Boost Lubricating eye drops.
Bausch + Lomb launches PF LUMIFY redness reliever drops
Products

Bausch + Lomb launches PF LUMIFY redness reliever drops

Newest preservative-free, OTC formulation of low-dose brimonidine tartrate is available in single-use vials to relieve eye redness due to minor ocular irritations.
B+L launches Zenlens CHROMA HOA scleral contact lenses
Products

B+L launches Zenlens CHROMA HOA scleral contact lenses

Newest addition to the scleral lens brand features a custom-designed, wavefront-guided scleral lens technology intended to correct advanced HOA.
B+L's enVista IOLs return to market after voluntary recall
Products

B+L's enVista IOLs return to market after voluntary recall

Company announces conclusion of investigation into reported cases of TASS involving the enVista IOL product line. 
B+L issues voluntary recall of certain IOLs in enVista platform
Products

B+L issues voluntary recall of certain IOLs in enVista platform

Recall follows an increase in reports of toxic anterior segment syndrome connected to implants of the enVista Aspire, Envy, and other monofocal IOLs.
Phase 4 data presents early patient-reported outcomes of MIEBO
Pipeline

Phase 4 data presents early patient-reported outcomes of MIEBO

Study finds symptom relief achieved as early as 5 to 60 minutes on day 1 of dosing—with significant reduction in overall severity after 14 days.
Bausch + Lomb launches ortho-k lens fitting system
Products

Bausch + Lomb launches ortho-k lens fitting system

The Arise cloud-based platform syncs directly with diagnostic tools to create a customized lens design for myopia treatment in mere seconds—without the need for a fitting set.
Eyecare companies offering support to LA wildfire victims
Events

Eyecare companies offering support to LA wildfire victims

Industry leaders such as CooperVision, Alcon, Bausch + Lomb, and EssilorLuxottica are providing supplies and services to optometrists and residents in need.
Bausch + Lomb may be acquiring InflammX Therapeutics
Business

Bausch + Lomb may be acquiring InflammX Therapeutics

Option agreement indicates B+L intends to purchase the biotech company and its orally-administered therapeutic under clinical investigation for retinal diseases.